鄰近類別 期刊論文 [32/32] 類別統計 近3年內發表的文件:7(87.50%) 含全文筆數:8(100.00%) 文件下載次數統計 下載大於0次:8(100.00%) 下載大於100次:6(75.00%) 檔案下載總次數:941(14.07%) 最後更新時間: 2024-12-13 00:16 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Aristolochic acid (AA) exposure and... Outcomes of post-immunotherapy dura... A phase II trial of nivolumab, gemc... Potential roles of gut microbiome i... Improved survival with neoadjuvant ... A phase II trial of nivolumab and g...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-8 / 8. (共1頁) 1  每頁顯示[10|25|50]項目

日期	題名	關聯
2023-11	Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome	Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
2023-11	Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis	Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537.
2023-06	Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)	Journal of Clinical Oncology. 2023 Jun;41(16 Suppl.):Meeting Abstract 11551.
2022-10	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression	Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-07	Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors	Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
2022-07	Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience	Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
2021-09	A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2021 Sep;32(Suppl. 5):S377.

顯示項目1-8 / 8. (共1頁) 1  每頁顯示[10|25|50]項目